NorthWest Biotherapeutics Inc (NWBO)

[Evaluate]

As seen at http://virtualtrials.com/Currently_Recruiting_Clinical_Trials_-_High_Grade_Glioma_treatments.cfm

The Jonsson Comprehensive Cancer Center at University of California, Los Angeles, is conducting this phase II trial for newly diagnosed or recurrent anaplastic gliomas or glioblastoma. Eligible patients must have surgery performed at UCLA to obtain tumor tissue to create the vaccine. The patient's own dendritic cells are pulsed with tumor lysate (from the patient's tumor tissue). The dendritic cells are then reinjected back into the patient, training the immune system to recognize patient-specific tumor antigens. This is the same method used in the DCVax trials. The current trial is randomizing patients to three arms: arm 1 receives the tumor-lysate pulsed dendritic cell vaccine plus placebo cream or saline injection; arm 2 receives vaccine plus resiquimod cream (an immune activator); and arm 3 receives vaccine plus intramuscular injection of Poly ICLC (another immune activator). Estimated enrollment in this trial is 60 patients, and estimated primary completion date is September 2014. NCT01204684

See also:
http://clinicaltrials.gov/show/NCT01204684